Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S MacKenzie

Showing results (641-650 of 662) with videos related to

Pageof 67
Sort By:
The Medical Journal of Australia|March 22, 2012
Murray Valley encephalitis: a review of clinical features, diagnosis and treatmentJames Knox, Raquel U Cowan, Joseph S Doyle, et al.
Lancet (London, England)|October 14, 2022
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trialIsla S Mackenzie, Amy Rogers, Neil R Poulter, et al.
Nature Communications|January 30, 2020
Hydrogen sulfide stimulates Mycobacterium tuberculosis respiration, growth and pathogenesisVikram Saini, Krishna C Chinta, Vineel P Reddy, et al.
Annals of the Rheumatic Diseases|November 30, 2021
Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritisRebecca A Symons, Fabio Colella, Fraser L Collins, et al.
Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.
British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Communicable Diseases Intelligence Quarterly Report|July 4, 2001
Murray Valley encephalitis virus surveillance and control initiatives in Australia. National Arbovirus Advisory Committee of the Communicable Diseases Network AustraliaJ D Spencer, J Azoulas, A K Broom, et al.
EMBO Molecular Medicine|December 7, 2020
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosisBei Shi Lee, Kiel Hards, Curtis A Engelhart, et al.
Pageof 67

Showing results (641-650 of 662) with videos related to

Sort By:
Pageof 67
The Medical Journal of Australia|March 22, 2012
Murray Valley encephalitis: a review of clinical features, diagnosis and treatmentJames Knox, Raquel U Cowan, Joseph S Doyle, et al.
Lancet (London, England)|October 14, 2022
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trialIsla S Mackenzie, Amy Rogers, Neil R Poulter, et al.
Nature Communications|January 30, 2020
Hydrogen sulfide stimulates Mycobacterium tuberculosis respiration, growth and pathogenesisVikram Saini, Krishna C Chinta, Vineel P Reddy, et al.
Annals of the Rheumatic Diseases|November 30, 2021
Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritisRebecca A Symons, Fabio Colella, Fraser L Collins, et al.
Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.
British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Communicable Diseases Intelligence Quarterly Report|July 4, 2001
Murray Valley encephalitis virus surveillance and control initiatives in Australia. National Arbovirus Advisory Committee of the Communicable Diseases Network AustraliaJ D Spencer, J Azoulas, A K Broom, et al.
EMBO Molecular Medicine|December 7, 2020
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosisBei Shi Lee, Kiel Hards, Curtis A Engelhart, et al.
Pageof 67